BioCentury
ARTICLE | Clinical News

TransMID-107R transferrin-mediated delivery of diphtheria toxin regulatory update

August 6, 2001 7:00 AM UTC

The FDA granted Fast Track status to KSB's TansMID-107R to treat recurrent, inoperable high-grade gliomas in adults. The product, which is expected to enter Phase III trials in 2002, was developed by ...